Aerie Pharmaceuticals (NASDAQ:AERI) Hits New 52-Week Low at $17.73
Aerie Pharmaceuticals Inc (NASDAQ:AERI) reached a new 52-week low on Wednesday . The company traded as low as $17.73 and last traded at $17.97, with a volume of 62698 shares. The stock had previously closed at $18.73.
A number of analysts have weighed in on the stock. BidaskClub raised shares of Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 11th. Canaccord Genuity set a $56.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, June 11th. Zacks Investment Research raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating and set a $31.00 target price on the stock in a research note on Friday, June 28th. Mizuho set a $63.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, September 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $57.00 target price on shares of Aerie Pharmaceuticals in a research note on Thursday, August 8th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $58.83.
The company has a quick ratio of 2.35, a current ratio of 2.52 and a debt-to-equity ratio of 0.08. The company has a market cap of $913.73 million, a P/E ratio of -3.87 and a beta of 0.53. The firm’s 50 day moving average is $21.32 and its two-hundred day moving average is $30.91.
In other Aerie Pharmaceuticals news, CFO Richard J. Rubino acquired 5,040 shares of Aerie Pharmaceuticals stock in a transaction that occurred on Monday, September 9th. The shares were bought at an average price of $19.93 per share, with a total value of $100,447.20. Following the completion of the purchase, the chief financial officer now directly owns 339,446 shares in the company, valued at approximately $6,765,158.78. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Foresite Capital Management Ii acquired 1,153 shares of Aerie Pharmaceuticals stock in a transaction that occurred on Wednesday, August 21st. The stock was acquired at an average cost of $23.25 per share, for a total transaction of $26,807.25. The disclosure for this purchase can be found here. In the last three months, insiders purchased 562,698 shares of company stock worth $13,088,866. 8.71% of the stock is currently owned by insiders.
Several institutional investors have recently modified their holdings of AERI. River & Mercantile Asset Management LLP acquired a new position in Aerie Pharmaceuticals in the second quarter valued at $1,562,000. Atria Investments LLC acquired a new position in Aerie Pharmaceuticals in the second quarter valued at $811,000. Chartwell Investment Partners LLC lifted its holdings in Aerie Pharmaceuticals by 66.6% in the second quarter. Chartwell Investment Partners LLC now owns 70,484 shares of the company’s stock valued at $2,083,000 after buying an additional 28,171 shares during the period. Platinum Investment Management Ltd. lifted its holdings in Aerie Pharmaceuticals by 71.6% in the second quarter. Platinum Investment Management Ltd. now owns 54,384 shares of the company’s stock valued at $1,607,000 after buying an additional 22,684 shares during the period. Finally, United Services Automobile Association lifted its holdings in Aerie Pharmaceuticals by 54.7% in the second quarter. United Services Automobile Association now owns 57,682 shares of the company’s stock valued at $1,705,000 after buying an additional 20,400 shares during the period.
About Aerie Pharmaceuticals (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Read More: Are we seeing the beginning of a new bubble?
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.